Clinical Trial Update: A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating the safety, tolerability, and preliminary efficacy of the investigational drug BxC-I17e given by subcutaneous injection i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• BxC-I17e

Snippet

Sponsor: Brexogen Inc. | Conditions: Atopic Dermatitis | Phase 1 | Status: RECRUITING